Cartesian Therapeutics, Inc. — Director's Dealing 2024

Nov 22, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2024-11-20

Reporting Person: Jewell Christopher M (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-11-20	Common Stock	M	14000	$3.23	Acquired	39940	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-11-20	Stock Option (Right to Buy)	$3.23	M	14000	Disposed	2033-01-15	Common Stock (14000)	Direct

Footnotes

F1: The option is currently exercisable for 123,235 shares of Common Stock and becomes exercisable for an additional 2,969 shares of Common Stock each month until it is fully exercisable on June 16, 2025.

F2: On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.